Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Market Cap	$629.38M	P/E Ratio	N/A
52W High	$10.02	52W Low	$0.78
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	93.6%
Overall Score	67	Value Score	60
Quality Score	--	Technical Score	75

EPS Current Est	$-1.5	EPS Next Est	$-1.93
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTYX	$9.43	-1.87%	1.83M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTYX	$9.43	-1.9%	1.83M
3
4
5
6

VTYX

VTYX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ventyx Biosciences Inc. Data in Excel

Get Ventyx Biosciences Inc. Data in Excel